NIKKEI 225
33,450.32 +41.93 (+0.13%) HANG SENG
17,077.83 -276.31 (-1.59%) CRUDE OIL
76.46 +0.05 (+0.07%) GOLD FUTURES
2,047.80 +7.80 (+0.38%) DOW
35,416.98 +83.51 (+0.24%) Bitcoin GBP
29,843.03 +607.90 (+2.08%)
Merck & Co., Inc. (0QAH.L)
| Previous close | 89.51 |
| Open | 92.36 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 89.12 - 89.48 |
| 52-week range | 84.53 - 119.56 |
| Volume | |
| Avg. volume | 63,990 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 0.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Merck Announces First-Quarter 2024 Dividend
RAHWAY, N.J., November 28, 2023--Merck Announces First-Quarter 2024 Dividend
- Business Wire
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
RAHWAY, N.J., November 28, 2023--Merck’s V116 an Investigational 21-valent PCV Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50+
- Business Wire
Merck to Acquire Caraway Therapeutics, Inc.
RAHWAY, N.J., & CAMBRIDGE, Mass., November 21, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment as well as contingent milestone payments. The upfront payment will be expensed by Merck in t
